MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates
MacroGenics (MGNX) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.84 per share a year ago.
MacroGenics (MGNX) Loses -48.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for MacroGenics (MGNX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
MacroGenics (MGNX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for MacroGenics (MGNX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates
MacroGenics (MGNX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.75 per share a year ago.
MacroGenics, Inc. (MGNX) Q4 2024 Earnings Call Transcript
MacroGenics, Inc. (NASDAQ:MGNX ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants James Karrels - SVP, CFO and Secretary Scott Koenig - President and CEO Stephen Eck - SVP, Clinical Development & Chief Medical Officer Conference Call Participants Peter Lawson - Barclays Jonathan Chang - Leerink Partners Nicholas Lorusso - TD Cowen Jonathan Miller - Evercore ISI Stephen Willey - Stifel Silvan Tuerkcan - Citizens JMP Securities Mayank Mamtani - B. Riley Securities Operator Good afternoon.
MacroGenics: Stacking Up A Lot Of Headwinds
MacroGenics' valuation has declined due to continued bad news in 2024, impacting market sentiment. MGNX holds $179.6M in cash and equivalents, with a sustainable cash burn rate for up to 5 years. Sale of the margetuximab franchise poises the company for further financial stability. Operating expenses are expected to rise as clinical programs advance, with management projecting a cash runway into 2026. I think this is a conservative estimate.
Here's What Key Metrics Tell Us About MacroGenics (MGNX) Q3 Earnings
The headline numbers for MacroGenics (MGNX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
MacroGenics (MGNX) Beats Q3 Earnings and Revenue Estimates
MacroGenics (MGNX) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to loss of $0.52 per share a year ago.
MacroGenics, Inc. (MGNX) Q2 2024 Earnings Call Transcript
MacroGenics, Inc. (NASDAQ:MGNX ) Q2 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants James Karrels - Senior Vice President, Chief Financial Officer and Secretary Scott Koenig - President and Chief Executive Officer Conference Call Participants Nicholas Lorusso - TD Cowen Jonathan Chang - Leerink Partners Reena Patel - Citi Etzer Darout - BMO Capital Markets Jonathan Miller - Evercore ISI Silvan Tuerkcan - Citizens JMP Securities Mayank Mamtani - B. Riley Securities Peter Lawson - Barclays Stephen Willey - Stifel Operator Good afternoon.
Rigrodsky Law, P.A. Is Investigating MacroGenics, Inc. On Behalf of Shareholders
WILMINGTON, DE / ACCESSWIRE / October 25, 2024 / Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ GS:MGNX) on behalf of stockholders.
Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – MGNX
NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 - MGNX
NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
